Blueprint Medicines Corporation

NasdaqGS:BPMC 주식 보고서

시가총액: US$6.3b

Blueprint Medicines 과거 수익 실적

과거 기준 확인 0/6

Blueprint Medicines의 수입은 연평균 -15.4%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 19.3%의 비율로 증가했습니다. 매출은 연평균 0.9%의 비율로 감소해 왔습니다.

주요 정보

-15.4%

수익 성장률

-11.9%

EPS 성장률

Biotechs 산업 성장17.0%
매출 성장률-0.9%
자기자본 수익률-40.9%
순이익-29.5%
최근 수익 업데이트30 Sep 2024

최근 과거 실적 업데이트

Recent updates

Blueprint Medicines: Growth For The Long Term Still Mostly Priced In

Sep 27

Is Blueprint Medicines (NASDAQ:BPMC) Using Too Much Debt?

Aug 16
Is Blueprint Medicines (NASDAQ:BPMC) Using Too Much Debt?

Some Confidence Is Lacking In Blueprint Medicines Corporation's (NASDAQ:BPMC) P/S

Jul 23
Some Confidence Is Lacking In Blueprint Medicines Corporation's (NASDAQ:BPMC) P/S

Blueprint Medicines: Overdue For A Breather

Jul 16

Blueprint Medicines Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 05
Blueprint Medicines Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Blueprint Medicines: Rampant Growth Mostly Priced In

May 04

Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Apr 26
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)

Apr 05
Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)

Feb 20

Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate

Jan 08
Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate

Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%

Dec 18
Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%

Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?

Nov 20
Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?

Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?

Jul 26
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?

Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?

Apr 16
Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?

Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 09
Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value

Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt

Dec 12
Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt

Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates

Nov 07
Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates

Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal

Sep 15

Blueprint to seek label expansion for systemic mastocytosis therapy after trial win

Aug 17

Blueprint Medicines reports Q2 earnings miss; reaffirms FY22 guidance

Aug 02

Blueprint to sell Ayvakit royalty for $250M upfront; Gavreto royalty for $175M upfront

Jun 30

수익 및 비용 분석

Blueprint Medicines 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

NasdaqGS:BPMC 수익, 비용 및 수입 (USD Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 24434-128342355
30 Jun 24363-205325378
31 Mar 24282-288308404
31 Dec 23249-507295428
30 Sep 23216-555280448
30 Jun 23226-554265468
31 Mar 23205-581251486
31 Dec 22204-558237477
30 Sep 22272-718228716
30 Jun 22230-702220673
31 Mar 22221-650210624
31 Dec 21180-644195601
30 Sep 21107-411184322
30 Jun 21828340171487
31 Mar 21809325164407
31 Dec 20794314158327
30 Sep 20811333147249
30 Jun 2075-3951360
31 Mar 2072-3711150
31 Dec 1967-34896331
30 Sep 1916-362780
30 Jun 198-340640
31 Mar 1944-267550
31 Dec 1845-237480
30 Sep 1845-205420
30 Jun 1852-170380
31 Mar 1817-177320
31 Dec 1721-148280
30 Sep 1727-120250
30 Jun 1726-99220
31 Mar 1727-85200
31 Dec 1628-72190
30 Sep 1625-67180
30 Jun 1622-63170
31 Mar 1618-58160
31 Dec 1511-56140
30 Sep 157-57140
30 Jun 153-56110
31 Mar 151-5290
31 Dec 140-4680

양질의 수익: BPMC 은(는) 현재 수익성이 없습니다.

이익 마진 증가: BPMC 은(는) 현재 수익성이 없습니다.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: BPMC 은(는) 수익성이 없으며 지난 5년 동안 연간 15.4% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 BPMC 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: BPMC 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 16.6% )와 비교하기 어렵습니다.


자기자본 수익률

높은 ROE: BPMC 현재 수익성이 없기 때문에 마이너스 자본 수익률( -40.89% )을 갖습니다.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기